Published in Nat Rev Cardiol on January 15, 2013
The Burmese python genome reveals the molecular basis for extreme adaptation in snakes. Proc Natl Acad Sci U S A (2013) 1.59
Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism (2014) 0.98
Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J Mol Cell Cardiol (2015) 0.91
Current and future G protein-coupled receptor signaling targets for heart failure therapy. Drug Des Devel Ther (2013) 0.86
Whole-thorax irradiation induces hypoxic respiratory failure, pleural effusions and cardiac remodeling. J Radiat Res (2014) 0.86
New medical therapies for heart failure. Nat Rev Cardiol (2015) 0.83
Managing sarcopenia and its related-fractures to improve quality of life in geriatric populations. Aging Dis (2013) 0.82
Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice. Acta Pharmacol Sin (2014) 0.82
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vasc Health Risk Manag (2015) 0.80
Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events. J Am Heart Assoc (2015) 0.78
Mas receptor mediates cardioprotection of angiotensin-(1-7) against Angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress. J Cell Mol Med (2015) 0.76
Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?". World J Cardiol (2015) 0.76
From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure. Heart Lung Circ (2016) 0.76
Transforming growth factor beta1 and aldosterone. Curr Opin Nephrol Hypertens (2015) 0.75
Photoreleasable ligands to study intracrine angiotensin II signalling. J Physiol (2015) 0.75
Molecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling. J Clin Med (2014) 0.75
A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart. Heart Fail Rev (2015) 0.75
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure. Diseases (2017) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med (2004) 11.44
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol (2006) 5.58
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA (2012) 4.57
Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA (2010) 4.36
The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2006) 4.10
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 3.39
B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol (2006) 3.37
Clinical practice. Systolic heart failure. N Engl J Med (2010) 3.26
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int (2008) 2.95
Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol (1995) 2.46
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation (2008) 2.41
Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med (2004) 2.39
Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension (2008) 2.21
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol (2009) 2.21
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens (2004) 1.90
Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res (2008) 1.88
High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation (2006) 1.82
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol (2012) 1.71
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation (2000) 1.70
Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension (2010) 1.69
Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol (1994) 1.68
Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation (1992) 1.65
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail (2008) 1.65
Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation (2002) 1.63
Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation (1997) 1.62
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol (1996) 1.60
Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol (2011) 1.60
Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ (2010) 1.59
The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol (2011) 1.51
Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. Nat Rev Cardiol (2011) 1.49
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation (2008) 1.45
Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens (2007) 1.44
Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. Heart Rhythm (2011) 1.41
Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res (1997) 1.24
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J (2011) 1.20
Renin, (pro)renin and receptor: an update. Clin Sci (Lond) (2011) 1.16
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail (2010) 1.15
Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation (2005) 1.15
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res (1992) 1.12
How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart (1999) 1.08
The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens (2007) 1.06
Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail (2010) 1.06
Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia (2008) 1.05
Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol (2001) 1.04
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. Am Heart J (2010) 1.03
Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet (2008) 1.02
Is there a future for renin inhibitors? Expert Opin Investig Drugs (2001) 1.01
Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol (2001) 1.01
Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol (1998) 0.98
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol (1995) 0.98
New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev (2012) 0.98
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail (1996) 0.97
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol (2007) 0.96
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens (1992) 0.94
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail (2012) 0.94
Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J (2010) 0.89
Influence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet (1991) 0.88
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation (2004) 0.88
Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats. Hypertension (1991) 0.87
Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate. J Urol (1975) 0.86
Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats. J Hypertens (2010) 0.85
Dual RAAS suppression: recent developments and implications in light of the ALTITUDE study. J Renin Angiotensin Aldosterone Syst (2012) 0.84
The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol (1997) 0.83
Heart failure therapy: what should clinicians believe? JAMA (2012) 0.83
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. Eur J Heart Fail (2011) 0.82
Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol (1996) 0.82
Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet (2010) 4.74
Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation (2002) 3.72
Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens (2010) 2.73
The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail (2010) 2.68
What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol (2004) 2.62
Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol (2012) 2.47
Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med (2013) 2.37
Peripheral blood pressure measurement is as good as applanation tonometry at predicting ascending aortic blood pressure. J Hypertens (2003) 2.12
Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens (2009) 1.95
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol (2011) 1.88
Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol (2011) 1.85
Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol (2002) 1.64
Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol (2011) 1.60
Pulse wave analysis and pulse wave velocity: a critical review of their strengths and weaknesses. J Hypertens (2003) 1.60
Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ (2010) 1.59
The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. Eur J Heart Fail (2012) 1.54
Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. Hypertension (2014) 1.53
Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ (2007) 1.51
The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J Hypertens (2002) 1.51
The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol (2011) 1.51
The cardiovascular risk factor, left ventricular hypertrophy, is highly prevalent in stable, treated angina pectoris. Am J Hypertens (2007) 1.50
Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol (2010) 1.50
High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart (2014) 1.45
Effect of spironolactone on physical performance in older people with self-reported physical disability. Am J Med (2013) 1.45
Time course for recovery of atrial mechanical and endocrine function post DC cardioversion for persistent atrial fibrillation. Int J Cardiol (2005) 1.45
Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens (2007) 1.44
Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol (2009) 1.41
Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. Heart Rhythm (2011) 1.41
Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) (2002) 1.31
Adverse cardiovascular effects of acute salt loading in young normotensive individuals. Hypertension (2008) 1.27
Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail (2002) 1.27
Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag (2009) 1.24
High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol (2013) 1.16
Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol (2011) 1.16
Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation (2003) 1.06
Effect of a seated exercise program to improve physical function and health status in frail patients > or = 70 years of age with heart failure. Am J Cardiol (2005) 1.02
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J (2012) 1.02
Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther (2008) 1.00
Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum (2012) 1.00
Allopurinol treatment reduces arterial wave reflection in stroke survivors. Cardiovasc Ther (2008) 0.99
Sarcopenia--a potential target for Angiotensin-converting enzyme inhibition? Gerontology (2006) 0.99
The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Ther (2008) 0.92
Optimization of the contrast dose and injection rates in whole-body MR angiography at 3.0T. J Magn Reson Imaging (2009) 0.92
Efficacy and cost of an exercise program for functionally impaired older patients with heart failure: a randomized controlled trial. Circ Heart Fail (2012) 0.91
Relation of QT interval dispersion to the number of different cardiac abnormalities in diabetes mellitus. Am J Cardiol (2002) 0.91
Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities. Am Heart J (2009) 0.91
Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol (2004) 0.91
Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Heart Fail (2011) 0.90
Effects of vitamin D supplementation on markers of vascular function after myocardial infarction--a randomised controlled trial. Int J Cardiol (2012) 0.88
B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. Age Ageing (2002) 0.86
Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people? Clin Endocrinol (Oxf) (2011) 0.86
Left ventricular hypertrophy in COPD without hypoxemia: the elephant in the room? Chest (2013) 0.85
B-type natriuretic peptide is an independent predictor of endothelial function in man. Clin Sci (Lond) (2012) 0.85
Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart (2002) 0.85
The association between serum urate levels and arterial stiffness/endothelial function in stroke survivors. Atherosclerosis (2008) 0.85
Effects of an exercise intervention for older heart failure patients on caregiver burden and emotional distress. Eur J Cardiovasc Prev Rehabil (2006) 0.84
Predictors of exercise capacity and everyday activity in older heart failure patients. Eur J Heart Fail (2005) 0.83
Meta-analysis of B-type natriuretic peptide's ability to identify stress induced myocardial ischemia. Am J Cardiol (2010) 0.83
The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. J Am Coll Cardiol (2002) 0.83
A critical re-appraisal of different ways of selecting ambulatory patients with suspected heart failure for echocardiography. Eur J Heart Fail (2006) 0.83
Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism. Respir Med (2005) 0.83
Exercise training as a therapy for chronic heart failure: can older people benefit? J Am Geriatr Soc (2003) 0.82
Screening for treatable left ventricular abnormalities in diabetic patients. Expert Opin Biol Ther (2003) 0.82
B-type natriuretic Peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure. Am J Hypertens (2005) 0.81
How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade? J Hypertens (2004) 0.80
C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure. Clin Sci (Lond) (2009) 0.80
Heart rate variability as an indicator of left ventricular systolic dysfunction. Cardiovasc J Afr (2009) 0.80
Hyperkalemia after the publication of RALES. N Engl J Med (2004) 0.79
Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens (2012) 0.79
N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy. Am J Cardiol (2011) 0.79
Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology. Cardiovasc Ther (2009) 0.79
B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus. Am J Cardiol (2005) 0.79
Atrial natriuretic peptide regulates regional vascular volume and venous tone in humans. Arterioscler Thromb Vasc Biol (2003) 0.79
Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study. Clin Exp Hypertens (2014) 0.79
Family history of premature coronary heart disease and risk prediction. Heart (2011) 0.79
The T allele of the C(677)T 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism may protect endothelial function in young, normal subjects. Arterioscler Thromb Vasc Biol (2002) 0.78
Left ventricular hypertrophy is present in one-half of newly-diagnosed peripheral arterial disease patients. J Hypertens (2007) 0.78
Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol (2006) 0.78
B-type natriuretic peptide and acute coronary syndromes. N Engl J Med (2002) 0.78
Myocardial ischaemia is associated with an elevated brain natriuretic pepide level even in the presence of left ventricular systolic dysfunction. Eur J Heart Fail (2013) 0.78
Polymorphisms of the angiotensin converting enzyme gene in early-onset and late-onset pre-eclampsia. J Matern Fetal Neonatal Med (2010) 0.78
Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. Br J Clin Pharmacol (2004) 0.78
Age is not a significant risk factor for failed trial of beta-blocker therapy in older patients with chronic heart failure. Age Ageing (2004) 0.78
B-type natriuretic peptide is associated with mortality in older functionally impaired patients. J Am Geriatr Soc (2005) 0.77
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. Eur J Heart Fail (2009) 0.77
Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients. J Renin Angiotensin Aldosterone Syst (2004) 0.77
Adherence to angiotensin-converting-enzyme inhibitors and illness beliefs in older heart failure patients. Eur J Heart Fail (2009) 0.77
Correlation of angiotensin converting enzyme activity and the genotypes of the I/D polymorphism in the ACE gene with preterm birth and birth weight. Eur J Obstet Gynecol Reprod Biol (2008) 0.77
Pentaerythrityl tetranitrate (PETN): a better nitrate? Eur Heart J (2013) 0.77
Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs (2003) 0.77
Development and validation of a clinical score to identify echocardiographic left ventricular hypertrophy in patients with cardiovascular disease. Am J Hypertens (2008) 0.77
Exercise capacity and brain natruiretic peptide in hypertension. J Cardiovasc Pharmacol (2002) 0.77
Using the demand-control model of job strain to predict caregiver burden and caregiver satisfaction in the informal caregivers of heart failure patients. Br J Health Psychol (2007) 0.76
Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones. Heart Fail Clin (2012) 0.76
Screening for left ventricular systolic dysfunction using GP-reported ECGs. Br J Gen Pract (2007) 0.76
Effect of vitamin D supplementation on orthostatic hypotension: data from the vitamin D in isolated systolic hypertension randomized controlled trial. J Hypertens (2014) 0.76
Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol (2004) 0.76
Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opin Pharmacother (2007) 0.76
Aortic valvular heart disease: Is there a place for angiotensin-converting-enzyme inhibitors? Expert Rev Cardiovasc Ther (2013) 0.76
Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study. Cardiovasc Ther (2008) 0.76